Table 8.
Clinicopathological characteristics of the Ruijin and SJTU cohorts’ combination by time to surgery after diagnosis.
| Characteristics | Before propensity score matched (N = 5130) | P value | After propensity score matched (N = 1484) | P value | ||||
|---|---|---|---|---|---|---|---|---|
| ≤ 1 week N = 4346 (%) |
1–2 weeks N = 538 (%) |
> 2 weeks N = 246 (%) |
≤ 1 week N = 1060 (%) |
1–2 weeks N = 212 (%) |
> 2 weeks N = 212 (%) |
|||
| Age (y/o) | ||||||||
| < 40 | 413 (9.5) | 85 (15.8) | 46 (18.7) | < 0.001 | 175 (16.5) | 37 (17.5) | 40 (18.9) | 0.403 |
| 40–49 | 1189 (27.4) | 172 (32.0) | 64 (26.0) | 365 (34.4) | 72 (34.0) | 57 (26.9) | ||
| 50–70 | 2344 (53.9) | 226 (42.0) | 109 (44.3) | 439 (41.4) | 85 (40.1) | 92 (43.4) | ||
| > 70 | 400 (9.2) | 55 (10.2) | 27 (11.0) | 81 (7.6) | 18 (8.5) | 23 (10.8) | ||
| CCI | ||||||||
| 0 | 2794 (64.3) | 360 (66.9) | 145 (58.9) | 0.003 | 659 (62.2) | 130 (61.3) | 128 (60.4) | 0.322 |
| 1–2 | 1189 (27.4) | 128 (23.8) | 64 (26.0) | 287 (27.1) | 54 (25.5) | 51 (24.1) | ||
| 3 + | 363 (8.4) | 50 (9.3) | 37 (15.0) | 114 (10.8) | 28 (13.2) | 33 (15.6) | ||
| Breast surgery | ||||||||
| BCS | 1250 (28.8) | 143 (26.6) | 57 (23.2) | 0.109 | 314 (29.6) | 57 (26.9) | 50 (23.6) | 0.179 |
| Mastectomy | 3096 (71.2) | 395 (73.4) | 189 (76.8) | 746 (70.4) | 155 (73.1) | 162 (76.4) | ||
| Axillary surgery | ||||||||
| SLNB | 2317 (53.3) | 252 (46.9) | 114 (46.3) | 0.003 | 539 (50.8) | 100 (47.2) | 98 (46.2) | 0.107 |
| ALND | 2010 (46.3) | 280 (52.0) | 129 (52.4) | 519 (49.0) | 109 (51.4) | 111 (52.4) | ||
| NA | 19 (0.4) | 6 (1.1) | 3 (1.2) | 2 (0.2) | 3 (1.4) | 3 (1.4) | ||
| Histology type | ||||||||
| IDC | 3852 (88.6) | 475 (88.3) | 214 (87.0) | 0.772 | 1007 (95.0) | 197 (92.9) | 195 (92.0) | 0.149 |
| Non-IDC | 494 (11.4) | 63 (11.7) | 32 (13.0) | 53 (5.0) | 15 (7.1) | 17 (8.0) | ||
| Tumor stage | ||||||||
| I | 1567 (36.1) | 176 (32.7) | 70 (28.5) | 0.026 | 279 (26.3) | 55 (25.9) | 56 (26.4) | 0.862 |
| II | 2084 (48.0) | 280 (52.0) | 141 (57.3) | 594 (56.0) | 122 (57.5) | 125 (59.0) | ||
| III | 695 (16.0) | 82 (15.2) | 35 (14.2) | 187 (17.7) | 35 (16.5) | 31 (14.6) | ||
| Histological grade | ||||||||
| I | 237 (5.5) | 31 (5.8) | 21 (8.5) | 0.016 | 84 (7.9) | 15 (7.1) | 21 (17.5) | 0.272 |
| II | 2375 (54.6) | 320 (59.5) | 130 (52.8) | 727 (68.6) | 144 (67.9) | 129 (60.8) | ||
| III | 1226 (29.1) | 122 (22.7) | 63 (25.6) | 249 (23.5) | 53 (25.0) | 62 (29.2) | ||
| NA | 468 (10.8) | 65 (12.1) | 32 (13.0) | 0 (0.0 | 0 (0.0) | 0 (0.0) | ||
| Molecular subtype | ||||||||
| HR + /HER2 − | 2638 (60.7) | 334 (62.1) | 150 (61.0) | 0.719 | 655 (61.8) | 125 (59.0) | 131 (61.8) | 0.731 |
| HER2 + | 1103 (25.4) | 137 (25.5) | 57 (23.2) | 262 (24.7) | 59 (27.8) | 48 (22.6) | ||
| TNBC | 605 (13.9) | 67 (12.5) | 39 (15.9) | 143 (13.5) | 28 (13.2) | 33 (15.6) | ||
Significant values are in bold.